Literature DB >> 9200444

Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells.

K Matsui1, T Yoshimoto, H Tsutsui, Y Hyodo, N Hayashi, K Hiroishi, N Kawada, H Okamura, K Nakanishi, K Higashino.   

Abstract

LPS injection into normal mice does not induce liver injury, while the same treatment of Propionibacterium acnes-primed mice induces severe liver injury, indicating that P. acnes treatment renders the mice susceptible to LPS. Since IFN-gamma sensitizes macrophages to LPS, we investigated the mechanism of induction and activation of IFN-gamma-producing (type 1) T cells by P. acnes. Twenty percent of liver lymphocytes of C57BL/6 mice are CD4+ NK1.1+ T cells that promptly produce IL-4 in response to anti-CD3 in vitro. However, P. acnes treatment diminished these lymphocytes. Therefore, liver lymphocytes from P. acnes-primed mice showed reduced IL-4 production. Furthermore, P. acnes treatment induced CD4- type 1 T cells in the liver. Isolated P. acnes-elicited Kupffer cells produced IL-12 and to a lesser degree IL-18 in vitro. Injection of anti-IL-12 Ab totally abrogated these actions of P. acnes, while injection of anti-IL-18 Ab caused only partial abrogation. Thus, administration of P. acnes diminished CD4+ NK1.1+ T cells, but induced type 1 T cells in the liver by induction of IL-12 and IL-18 production. Injection of IL-12 (approximately 1,000 ng) dose dependently diminished CD4+ NK1.1+ T cells, but induced type 1 T cells. In contrast, injection of IL-18 (approximately 1,000 ng) failed, although injection of a much larger dose of IL-18 (10,000 ng) or IL-18 (approximately 1,000 ng) with suboptimal doses of IL-12 (1-100 ng) diminished CD4+ NK1.1+ T cells in a dose-dependent manner. Thus, P. acnes treatment renders the mice highly susceptible to LPS by induction and activation of type 1 T cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9200444

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice.

Authors:  I Sugawara; H Yamada; H Kaneko; S Mizuno; K Takeda; S Akira
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease.

Authors:  Othmar Ludwiczek; Arthur Kaser; Daniela Novick; Charles A Dinarello; Menachem Rubinstein; Wolfgang Vogel; Herbert Tilg
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

3.  Both CD1d antigen presentation and interleukin-12 are required to activate natural killer T cells during Trypanosoma cruzi infection.

Authors:  Malcolm S Duthie; Maria Kahn; Maria White; Raj P Kapur; Stuart J Kahn
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

4.  Role of CTLA-4, IL-18 and IL-10 on the Induction of Low Dose Oral Tolerance.

Authors:  Kathleen Siobhan Barone; Rachael Burns; Stephanie Horton; Armando Retana; Lindsey Jackson Meredith Wall; Tifany Nolan
Journal:  J Ky Acad Sci       Date:  2008-03-01

Review 5.  Genetic polymorphisms of cytokine genes in type 2 diabetes mellitus.

Authors:  Monisha Banerjee; Madhukar Saxena
Journal:  World J Diabetes       Date:  2014-08-15

6.  Hepatic RNA Interference: Delivery by Synthetic Vectors.

Authors:  Matthew Haynes; Leaf Huang
Journal:  Drug Deliv Transl Res       Date:  2014-02-01       Impact factor: 4.617

7.  IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation.

Authors:  B Siegmund; H A Lehr; G Fantuzzi; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

8.  Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells.

Authors:  M Miettinen; S Matikainen; J Vuopio-Varkila; J Pirhonen; K Varkila; M Kurimoto; I Julkunen
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

Review 9.  Interleukin 18 in the CNS.

Authors:  Silvia Alboni; Davide Cervia; Shuei Sugama; Bruno Conti
Journal:  J Neuroinflammation       Date:  2010-01-29       Impact factor: 8.322

Review 10.  The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases.

Authors:  Cem Gabay; Iain B McInnes
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.